

July 1, 2026

To whom it may concern

Company Name: Innovacell Inc.
Representative: Representative Director Co-CEO
Colin Novick
Representative: Representative Director Co-CEO
Jason Sieger
(Code No.: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director CFO Yasushi Hosono
(<https://innovacell.com/contact/?lang=en>)

Announcement Regarding Co-CEO's Participation in FUNDINNO's MeetUp Event for Professional Investors

We are pleased to announce that our Co-CEOs, Colin Novick and Jason Sieger, participated in a MeetUp event for Professional Investors (*1) hosted by FUNDINNO, Inc. (hereinafter "FUNDINNO") on June 10, 2026, and that FUNDINNO has published an article introducing the event on its official IR account (IRnote).

Article URL: https://note.com/ir_fundinno/n/nbc1f25d9d397 (Japanese only)

Publication Date: June 30, 2026

This event was primarily aimed at individual investors using FUNDINNO's "FUNDINNO PLUS+" service, which enables Professional Investors to invest directly in unlisted companies. It was held in three parts: Part 1: Presentation by Innovacell; Part 2: Q&A Session; and Part 3: Networking Reception. In Part 1, our Co-CEOs presented on business progress, focusing on the previously announced financial results for the first quarter of the fiscal year ending December 2026. During the Q&A session in Part 2, there was a lively exchange of questions and answers between event participants and our Co-CEOs.

Feedback from event participants included comments such as, "I had been curious about the Company's situation following the IPO, so it was very meaningful to hear directly from both Co-CEOs on this occasion."

Going forward, Innovacell will continue to actively engage in dialogue with investors to broaden interest in and understanding of our business.

(*1) A "Professional Investor" is an investor who is generally considered to possess sufficient knowledge and experience regarding financial products, as well as the necessary assets and risk management capabilities. Consequently, this system provides an exemption from certain regulatory requirements under the law when financial instruments business operators develop or solicit financial products specifically for such investors.

■ About FUNDINNO, Inc. (<https://corp.fundinno.com/>)

FUNDINNO, Inc. (listed on the TSE Growth Market, code 462A) has adopted the mission of "eliminating information and opportunity gaps for all entrepreneurs and investors, and 'create a future where everyone can compete on a level playing field,' and operates services such as "FUNDINNO," Japan's first equity-based crowdfunding service, and "FUNDINNO PLUS+," which matches unlisted companies seeking large-scale funding with Professional Investors interested in angel investing in unlisted startups.

■ **About Innovacell Inc. (<https://innovacell.com/?lang=en>)**

The predecessor of Innovacell Inc. was a cell therapy start-up company spun out from the Medical University of Innsbruck (Austria). Innovacell Inc. was established in Japan in 2021 as the parent company of said Austrian company (currently Innovacell GmbH).

Innovacell group aims to improve patient health and QOL through the development and commercialization of cell therapies and regenerative medicine. It is currently focused on developing and commercializing regenerative medicine products for the treatment of urge and passive fecal incontinence as well as stress urinary incontinence.

ICEF15, the most advanced of the Group's pipeline products, aims to treat urge fecal incontinence by regenerating muscle tissue via the local administration of a patient's own skeletal myoblasts. ICEF15 is currently undergoing a multi-regional Phase III clinical trial in 11 European countries and Japan.

To date, Innovacell GmbH has completed multiple clinical trials in Europe, including Phase IIb trials for ICEF15 (urge fecal incontinence) and ICES13 (stress urinary incontinence).

End